These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

220 related items for PubMed ID: 10519405

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Inhibition of the prenylation of K-Ras, but not H- or N-Ras, is highly resistant to CAAX peptidomimetics and requires both a farnesyltransferase and a geranylgeranyltransferase I inhibitor in human tumor cell lines.
    Lerner EC, Zhang TT, Knowles DB, Qian Y, Hamilton AD, Sebti SM.
    Oncogene; 1997 Sep; 15(11):1283-8. PubMed ID: 9315095
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models.
    Lobell RB, Omer CA, Abrams MT, Bhimnathwala HG, Brucker MJ, Buser CA, Davide JP, deSolms SJ, Dinsmore CJ, Ellis-Hutchings MS, Kral AM, Liu D, Lumma WC, Machotka SV, Rands E, Williams TM, Graham SL, Hartman GD, Oliff AI, Heimbrook DC, Kohl NE.
    Cancer Res; 2001 Dec 15; 61(24):8758-68. PubMed ID: 11751396
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Disruption of oncogenic K-Ras4B processing and signaling by a potent geranylgeranyltransferase I inhibitor.
    Lerner EC, Qian Y, Hamilton AD, Sebti SM.
    J Biol Chem; 1995 Nov 10; 270(45):26770-3. PubMed ID: 7592913
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Antitumor activity of ER-51785, a new peptidomimetic inhibitor of farnesyl transferase: synergistic effect in combination with paclitaxel.
    Nakamura K, Yamaguchi A, Namiki M, Ishihara H, Nagasu T, Kowalczyk JJ, Garcia AM, Lewis MD, Yoshimatsu K.
    Oncol Res; 2001 Nov 10; 12(11-12):477-84. PubMed ID: 11939411
    [Abstract] [Full Text] [Related]

  • 9. Synergistic cytotoxic effects in myeloid leukemia cells upon cotreatment with farnesyltransferase and geranylgeranyl transferase-I inhibitors.
    Morgan MA, Wegner J, Aydilek E, Ganser A, Reuter CW.
    Leukemia; 2003 Aug 10; 17(8):1508-20. PubMed ID: 12886237
    [Abstract] [Full Text] [Related]

  • 10. Combining prenylation inhibitors causes synergistic cytotoxicity, apoptosis and disruption of RAS-to-MAP kinase signalling in multiple myeloma cells.
    Morgan MA, Sebil T, Aydilek E, Peest D, Ganser A, Reuter CW.
    Br J Haematol; 2005 Sep 10; 130(6):912-25. PubMed ID: 16156861
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Combination of the novel farnesyltransferase inhibitor RPR130401 and the geranylgeranyltransferase-1 inhibitor GGTI-298 disrupts MAP kinase activation and G(1)-S transition in Ki-Ras-overexpressing transformed adrenocortical cells.
    Mazet JL, Padieu M, Osman H, Maume G, Mailliet P, Dereu N, Hamilton AD, Lavelle F, Sebti SM, Maume BF.
    FEBS Lett; 1999 Oct 29; 460(2):235-40. PubMed ID: 10544242
    [Abstract] [Full Text] [Related]

  • 13. Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies.
    Sebti SM, Hamilton AD.
    Oncogene; 2000 Dec 27; 19(56):6584-93. PubMed ID: 11426643
    [Abstract] [Full Text] [Related]

  • 14. The geranylgeranyltransferase-I inhibitor GGTI-298 arrests human tumor cells in G0/G1 and induces p21(WAF1/CIP1/SDI1) in a p53-independent manner.
    Vogt A, Sun J, Qian Y, Hamilton AD, Sebti SM.
    J Biol Chem; 1997 Oct 24; 272(43):27224-9. PubMed ID: 9341167
    [Abstract] [Full Text] [Related]

  • 15. A non-peptide mimetic of Ras-CAAX: selective inhibition of farnesyltransferase and Ras processing.
    Vogt A, Qian Y, Blaskovich MA, Fossum RD, Hamilton AD, Sebti SM.
    J Biol Chem; 1995 Jan 13; 270(2):660-4. PubMed ID: 7822292
    [Abstract] [Full Text] [Related]

  • 16. Ras CAAX peptidomimetic FTI 276 selectively blocks tumor growth in nude mice of a human lung carcinoma with K-Ras mutation and p53 deletion.
    Sun J, Qian Y, Hamilton AD, Sebti SM.
    Cancer Res; 1995 Oct 01; 55(19):4243-7. PubMed ID: 7671229
    [Abstract] [Full Text] [Related]

  • 17. Selective inhibition of type-I geranylgeranyltransferase in vitro and in whole cells by CAAL peptidomimetics.
    Qian Y, Vogt A, Vasudevan A, Sebti SM, Hamilton AD.
    Bioorg Med Chem; 1998 Mar 01; 6(3):293-9. PubMed ID: 9568283
    [Abstract] [Full Text] [Related]

  • 18. Discovery of a series of cyclohexylethylamine-containing protein farnesyltransferase inhibitors exhibiting potent cellular activity.
    Henry KJ, Wasicak J, Tasker AS, Cohen J, Ewing P, Mitten M, Larsen JJ, Kalvin DM, Swenson R, Ng SC, Saeed B, Cherian S, Sham H, Rosenberg SH.
    J Med Chem; 1999 Nov 18; 42(23):4844-52. PubMed ID: 10579847
    [Abstract] [Full Text] [Related]

  • 19. A novel protein geranylgeranyltransferase-I inhibitor with high potency, selectivity, and cellular activity.
    Peterson YK, Kelly P, Weinbaum CA, Casey PJ.
    J Biol Chem; 2006 May 05; 281(18):12445-50. PubMed ID: 16517596
    [Abstract] [Full Text] [Related]

  • 20. Preclinical antitumor activity of BMS-214662, a highly apoptotic and novel farnesyltransferase inhibitor.
    Rose WC, Lee FY, Fairchild CR, Lynch M, Monticello T, Kramer RA, Manne V.
    Cancer Res; 2001 Oct 15; 61(20):7507-17. PubMed ID: 11606387
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.